CF
LGND icon

Corebridge Financial’s Ligand Pharmaceuticals LGND Stock Holding History

Corebridge Financial’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,384
Closed -$987K – 1518
2025
Q1 		$987K Buy
9,384
+109
+1% +$12.3K 0.01% 1260
2024
Q4 		$994K Sell
9,275
-544
-6% -$61.5K 0.01% 1330
2024
Q3 		$983K Sell
9,819
-48
-0.5% -$4.83K 0.01% 1368
2024
Q2 		$831K Buy
+9,867
New +$785K ﹤0.01% 1431

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corebridge Financial's LGND Position: Q2 2025 in Review

Corebridge Financial sold out of Ligand Pharmaceuticals (LGND) in Q2 2025, closing a stake of 9,384 shares — an estimated $987K sold.

Corebridge Financial first reported a position in LGND in Q2 2024 and held it in 4 quarters. The position peaked at $994K in Q4 2024. 271 funds tracked by Wall St. Rank hold LGND as of Q2 2025.

  • Corebridge Financial reported no remaining Ligand Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 9,384 Ligand Pharmaceuticals shares in Q2 2025, an estimated $987K.
  • Corebridge Financial first reported a position in Ligand Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Ligand Pharmaceuticals position peaked at $994K in Q4 2024.
  • 271 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.